As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >
#Health & well-being
ByoRNA is developing a platform for the bioproduction of RNA through fermentation in eukaryotic cells, a paradigm shift from in vitro synthesis.
BACKGROUND
ByoRNA was created in September 2022 by Pascal Viguié, a seasoned entrepreneur, and Thierry Ziegler, a veteran of pharmaceutical bioproduction, with scientific support from Chantal Pichon, a specialist in messenger RNA.
DESCRIPTION OF PRODUCTS / SERVICES / TECHNOLOGY
The technology developed by ByoRNA enables the production of humanized messenger RNA (mRNA) in a traditional bioreactor using a single cell culture. The industrialized process will be less expensive than the current multi-enzyme synthesis, which requires a different cell culture for each enzyme. The mRNA will be used for the development of new gene therapies and cancer vaccines.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
ByoRNA is a laureate from the Génopole Gene.Io program, and has been selected to be part of the first incubation/investment cohort of Antler Capital in France. In November 2022, we were granted the development license of a disruptive RNA bioproduction patent from a major French research organization.
COLLABORATIONS SOUGHT
We are looking for partnerships with biotech companies in the pre-clinical phase, developing therapies requiring large quantities of RNA (e.g.: rare diseases).
Strengths: large-scale, low-cost RNA production. Experienced and complementary team targeting a fast-growing market.
Innovation assets: breakthrough technology based on a French patent.
In the same field
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Discover
Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.
Discover
Kyron.Bio is a biotech company using synthetic biology to produce new therapies with high yield, activity, and stability standards.
Discover
CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.
Discover
Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.
Discover
Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.
Discover
Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.
Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies
Discover
Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.
Discover
Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease
Discover
Artificial intelligence to optimize and accelerate the development of gene therapies
Discover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).
Discover
Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.
Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.
Discover
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).
Discover
IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.
Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.
Discover
